Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology
- 13 September 2017
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 102 (5) , 593-598
Abstract
Purpose The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Design The LiGHT Trial is a prospective, unmasked, multicentre, pragmatic, randomised controlled trial. 718 previously untreated patients with POAG or OHT were recruited at six collaborating centres in the UK between 2012 and 2014. The trial comprises two treatment arms: initial SLT followed by conventional medical therapy as required, and medical therapy without laser therapy. Randomisation was provided online by a web-based randomisation service. Participants will be monitored for 3 years, according to routine clinical practice. The target intraocular pressure (IOP) was set at baseline according to an algorithm, based on disease severity and lifetime risk of loss of vision at recruitment, and subsequently adjusted on the basis of IOP control, optic disc and visual field. The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiveness, visual function and safety profiles and concordance. A single main analysis will be performed at the end of the trial on an intention-to-treat basis. Conclusions The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication. Trial registration number ISRCTN32038223, Pre-results.Keywords
Funding Information
- Health Technology Assessment Programme
This publication has 22 references indexed in Scilit:
- Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle GlaucomaAmerican Journal of Ophthalmology, 2016
- Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trialThe Lancet, 2015
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medicationsClinical Ophthalmology, 2010
- Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the USCurrent Medical Research and Opinion, 2008
- Glaucoma and MortalityOphthalmology, 2008
- Developing a Preference‐Based Glaucoma Utility Index Using a Discrete Choice ExperimentOptometry and Vision Science, 2007
- Risk of Falls and Motor Vehicle Collisions in GlaucomaInvestigative Ophthalmology & Visual Science, 2007
- The number of people with glaucoma worldwide in 2010 and 2020British Journal of Ophthalmology, 2006
- The Glaucoma Symptom ScaleArchives of Ophthalmology (1950), 1998